Progression-free survival for CLL patients receiving concurrent or sequential treatment.

Progression-free survival for 51 patients with CLL treated with a concurrent fludarabine and rituximab regimen (unbroken line) and 53 similar patients treated with a sequential fludarabine and rituximab regimen (dashed line) on CALGB 9712. Eighteen patients on the concurrent arm have experienced a relapse, and 15 patients on the sequential arm have experienced a relapse.